Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice.
Intravenous inoculation of BCG was found to be both prophylactic and therapeutic in BALB/c mice against challenge with amastigotes of Leishmania donovani. Spleens and livers of mice inoculated with BCG maintained total parasite burdens at significantly lower levels when compared to controls. BCG administered intravenously 14 days prior to and on the same day of protozoan challenge was more protective than vaccine given 30 and 14 days prior to challenge. A level of 10(7) viable units of BCG provided more protection against challenge with parasites than did 10(6) viable units. BCG given the same route as the challenge dose of amastigotes provided more protection than if administered via some other route. BCG given to mice with an already established infection was shown to significantly reduce their parasite burdens.
D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D006224:Cricetinae; D005260:Female; D007891:Leishmania / Q000254:growth & development; D007898:Leishmaniasis, Visceral / Q000517:prevention & control / Q000628:therapy*; D008099:Liver / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D013154:Spleen / Q000469:parasitology
D001500:BCG Vaccine